Analystreport

Akebia Therapeutics (NASDAQ:AKBA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.

Akebia Therapeutics, Inc.  (AKBA) 
Last akebia therapeutics, inc. earnings: 3/10 07:49 am Check Earnings Report
US:NASDAQ Investor Relations: ir.akebia.com/investor-relations